A Virtual Pyrogram Generator to Resolve Complex Pyrosequencing Results

被引:20
作者
Chen, Guoli
Olson, Matthew Theodore
O'Neill, Alan
Norris, Alexis
Beierl, Katie
Harada, Shuko
Debeljak, Marija
Rivera-Roman, Keila
Finley, Samantha
Stafford, Amanda
Gocke, Christopher David [2 ]
Lin, Ming-Tseh
Eshleman, James Richard [1 ,2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Dept Pathol, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA
关键词
K-RAS MUTATIONS; COLORECTAL-CANCER; KRAS MUTATION; DNA; CETUXIMAB; GENE; LUNG; RESISTANCE; MISMATCHES; THERAPY;
D O I
10.1016/j.jmoldx.2011.12.001
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We report a freely available software program, Pyromaker, which generates simulated traces for pyrosequencing results based on user inputs. Simulated pyrograms can aid in the analysis of complex pyrosequencing results in which various hypothesized mutations can be tested, and the resultant pyrograms can be matched with the actual pyrogram. We validated the software using the actual pyrograms for common KRAS gene mutations as well as several mutations in the BRAF, GNAS,, and P53 genes. We demonstrate that all 18 possible single-base mutations within codons 12 and 13 of KRAS generate unique pyrosequencing traces and highlight the distinctions between them. We further show that all reported codon 12 and 13 complex mutations produce unique pyrograms.. However, some complex mutations are indistinguishable from single-base mutations. For complicated pyrograms, Pyromaker was used in two modes, one in which hypothesis-based simulated pyrograms were pattern-matched with the actual pyrograms. In a. second strategy with only the pyrogram, Pyromaker was used to identify the underlying mutation by iteratively reconstructing the mutant pyrogram. Either strategy was able to successfully identify the complex mutations, which were confirmed by cloning and sequencing. Using two examples of KRAS codon 12 mutations (specifically GGT -> TTT, G12F and GGT -> GAG, G12E), we report which combinations of five approaches permit unambiguous mutation identification. The most efficient approach was found to be pyrosequencing with Pyromaker. J Mol Diagn 2012, 14:149-159; DOI:10.1016/j.jmoldx.2011.12.001)
引用
收藏
页码:149 / 159
页数:11
相关论文
共 20 条
[1]   Pyrosequencing: History, biochemistry and future [J].
Ahmadian, A ;
Ehn, M ;
Hober, S .
CLINICA CHIMICA ACTA, 2006, 363 (1-2) :83-94
[2]   PREVALENCE OF RAS GENE-MUTATIONS IN HUMAN COLORECTAL CANCERS [J].
BOS, JL ;
FEARON, ER ;
HAMILTON, SR ;
VERLAANDEVRIES, M ;
VANBOOM, JH ;
VANDEREB, AJ ;
VOGELSTEIN, B .
NATURE, 1987, 327 (6120) :293-297
[3]   Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab [J].
De Roock, Wendy ;
Jonker, Derek J. ;
Di Nicolantonio, Federica ;
Sartore-Bianchi, Andrea ;
Tu, Dongsheng ;
Siena, Salvatore ;
Lamba, Simona ;
Arena, Sabrina ;
Frattini, Milo ;
Piessevaux, Hubert ;
Van Cutsem, Eric ;
O'Callaghan, Chris J. ;
Khambata-Ford, Shirin ;
Zalcberg, John R. ;
Simes, John ;
Karapetis, Christos S. ;
Bardelli, Alberto ;
Tejpar, Sabine .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (16) :1812-1820
[4]   ALTERED GENE-PRODUCTS ARE ASSOCIATED WITH ACTIVATION OF CELLULAR RASK GENES IN HUMAN-LUNG AND COLON CARCINOMAS [J].
DER, CJ ;
COOPER, GM .
CELL, 1983, 32 (01) :201-208
[5]   THE P21 SRC GENES OF HARVEY AND KIRSTEN SARCOMA-VIRUSES ORIGINATE FROM DIVERGENT MEMBERS OF A FAMILY OF NORMAL VERTEBRATE GENES [J].
ELLIS, RW ;
DEFEO, D ;
SHIH, TY ;
GONDA, MA ;
YOUNG, HA ;
TSUCHIDA, N ;
LOWY, DR ;
SCOLNICK, EM .
NATURE, 1981, 292 (5823) :506-511
[6]   A NEW METHOD OF SEQUENCING DNA [J].
HYMAN, ED .
ANALYTICAL BIOCHEMISTRY, 1988, 174 (02) :423-436
[7]   Core signaling pathways in human pancreatic cancers revealed by global genomic analyses [J].
Jones, Sian ;
Zhang, Xiaosong ;
Parsons, D. Williams ;
Lin, Jimmy Cheng-Ho ;
Leary, Rebecca J. ;
Angenendt, Philipp ;
Mankoo, Parminder ;
Carter, Hannah ;
Kamiyama, Hirohiko ;
Jimeno, Antonio ;
Hong, Seung-Mo ;
Fu, Baojin ;
Lin, Ming-Tseh ;
Calhoun, Eric S. ;
Kamiyama, Mihoko ;
Walter, Kimberly ;
Nikolskaya, Tatiana ;
Nikolsky, Yuri ;
Hartigan, James ;
Smith, Douglas R. ;
Hidalgo, Manuel ;
Leach, Steven D. ;
Klein, Alison P. ;
Jaffee, Elizabeth M. ;
Goggins, Michael ;
Maitra, Anirban ;
Iacobuzio-Donahue, Christine ;
Eshleman, James R. ;
Kern, Scott E. ;
Hruban, Ralph H. ;
Karchin, Rachel ;
Papadopoulos, Nickolas ;
Parmigiani, Giovanni ;
Vogelstein, Bert ;
Velculescu, Victor E. ;
Kinzler, Kenneth W. .
SCIENCE, 2008, 321 (5897) :1801-1806
[8]   K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J].
Karapetis, Christos S. ;
Khambata-Ford, Shirin ;
Jonker, Derek J. ;
O'Callaghan, Chris J. ;
Tu, Dongsheng ;
Tebbutt, Niall C. ;
Simes, R. John ;
Chalchal, Haji ;
Shapiro, Jeremy D. ;
Robitaille, Sonia ;
Price, Timothy J. ;
Shepherd, Lois ;
Au, Heather-Jane ;
Langer, Christiane ;
Moore, Malcolm J. ;
Zalcberg, John R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17) :1757-1765
[9]   KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer [J].
Lièvre, A ;
Bachet, JB ;
Le Corre, D ;
Boige, V ;
Landi, B ;
Emile, JF ;
Côté, JF ;
Tomasic, G ;
Penna, C ;
Ducreux, M ;
Rougier, P ;
Penault-Llorca, F ;
Laurent-Puig, P .
CANCER RESEARCH, 2006, 66 (08) :3992-3995
[10]   KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer [J].
Massarelli, Erminia ;
Varella-Garcia, Marileila ;
Tang, Ximing ;
Xavier, Ana C. ;
Ozburn, Natalie C. ;
Liu, Diane D. ;
Bekele, Benjamin N. ;
Herbst, Roy S. ;
Wistuba, Ignacio I. .
CLINICAL CANCER RESEARCH, 2007, 13 (10) :2890-2896